YD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection

Core Insights - YD Bio Limited is expanding its OkaiDx platform for cancer detection, now including pancreatic and colorectal cancer tests in addition to breast cancer monitoring [1][2] - The company has established partnerships to integrate OkaiDx testing into primary care and women's health settings, enhancing accessibility for proactive cancer detection [3] - Recent clinical data shows the OkaiDx Detect Pancreatic Cancer Test has high sensitivity and specificity, indicating its potential effectiveness in early-stage cancer detection [4] Company Developments - YD Bio has broadened the availability of its OkaiDx blood-based testing services across 44 states in the U.S. through EG BioMed's accredited laboratory [2] - The company is leveraging a nationwide telehealth network to facilitate virtual consultations and streamline blood sample collection for patients [2] - New memorandums of understanding with medical groups aim to incorporate OkaiDx testing into routine clinical workflows [3] Clinical Advancements - The OkaiDx Detect Pancreatic Cancer Test demonstrated 93.8% sensitivity for early-stage pancreatic ductal adenocarcinoma and 100% sensitivity for late-stage cases [4] - The test also showed 97.3% specificity in healthy individuals and 97.7% overall accuracy in a study involving 100 PDAC patients and 500 healthy controls [4] - The findings highlight the potential of cfDNA methylation biomarkers, such as ZFP30, in improving early cancer detection [4]